aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone858-731-8389
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees42
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings results on Monday, May, 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. View aTyr Pharma's Earnings History.
When is aTyr Pharma's next earnings date?
What price target have analysts set for LIFE?
4 Wall Street analysts have issued 12-month target prices for aTyr Pharma's shares. Their forecasts range from $0.75 to $1.80. On average, they anticipate aTyr Pharma's stock price to reach $1.1833 in the next year. This suggests a possible upside of 167.1% from the stock's current price. View Analyst Price Targets for aTyr Pharma.
What is the consensus analysts' recommendation for aTyr Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.
Has aTyr Pharma been receiving favorable news coverage?
Media headlines about LIFE stock have trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. aTyr Pharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Are investors shorting aTyr Pharma?
aTyr Pharma saw a decrease in short interest in April. As of April 15th, there was short interest totalling 434,783 shares, a decrease of 33.8% from the March 29th total of 656,761 shares. Based on an average daily trading volume, of 338,705 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.9% of the company's shares are sold short. View aTyr Pharma's Current Options Chain.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Applied Genetic Technologies (AGTC), Curis (CRIS), Cidara Therapeutics (CDTX), BioCardia (BCDA), Pharmacyte Biotech (PMCB), Entera Bio (ENTX), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL), Outlook Therapeutics (OTLK) and TRACON Pharmaceuticals (TCON).
What other stocks do shareholders of aTyr Pharma own?
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
- Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)
- Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
- Dr. David J. King, Scientific Consultant (Age 60)
- Xiang-Lei Yang Ph.D., Founder
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Who are aTyr Pharma's major shareholders?
aTyr Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Viking Global Investors LP (8.79%) and Renaissance Technologies LLC (4.22%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Ecor1 Capital Fund Qualified,, Jill Marie Broadfoot, John Mendlein, Nancy Krueger and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.
Which institutional investors are buying aTyr Pharma stock?
LIFE stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP and Renaissance Technologies LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $0.4430.
How big of a company is aTyr Pharma?
aTyr Pharma has a market capitalization of $20.26 million. The biotechnology company earns $-34,510,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. aTyr Pharma employs 42 workers across the globe.
What is aTyr Pharma's official website?
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
